Biotech Influence in Exploding Cannabis Industry Boosting Innovative Treatments and Therapies

Tuesday, March 14, 2017 Drug News
Email Print This Page Comment
Font : A-A+

PALM BEACH, Florida, March 14, 2017 /PRNewswire/ --

MarketNewsUpdates.com News Commentary

Biotech

companies continue to increase their involvement in medicinal cannabis, as the industry enjoys significant growth and optimism. Operating with the business goals of following governmental mandates and industry standards, research and development, as
well as production of services, therapies and leading edge products are providing growth opportunities for companies such as: Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), Earth Science Tech, Inc. (OTC: ETST), CV Sciences, Inc. (OTC: CVSI), Medical Marijuana, Inc. (OTC: MJNA) and even biotech leaders like Cerulean Pharma Inc. (NASDAQ: CERU).

Earth Science Tech, Inc. (OTC: ETST), an innovative biotech company focused on cannabis (industrial hemp), cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, is proud to announce its subsidiaries Cannabis Therapeutic, Inc. and Earth Science Pharmaceutical, Inc., the nomination of Kim Foster-Cunningham to the post of Project Manager for the MSN-2 medical device project; and Denis Babin of SDB Import/Export, Inc. as international marketing consultant for Cannabis Therapeutics and Earth Science Pharmaceutical products. Read this and more news for Earth Science Tech at: http://marketnewsupdates.com/news/etst.html

Highlights from the ETST News include: Ms. Foster-Cunningham's immediate focus is on the preparatory phase of the pre-market clinical trial of the MSN-2 medical device. The MSN-2 device is a revolutionary medical instrument for the detection and diagnosis of Chlamydia and Gonorrhea, from previous announcement, (ETST Announces 60-Patient Clinical Prelaunch Study for its MSN-2 Medical Device for the Diagnosis of Chlamydia & Gonorrhea, ETST Elects Dr. Michel Aubé as New CEO & CSO, and Nickolas Tabraue as President.) Ms. Foster-Cunningham, who holds a degree in sales and marketing, is recognized for her expertise in business networking and her solid business expertise. She is a sought-after speaker throughout the USA and Canada, delivering conferences on her proactive approach to general health and self-care. Passionate about individual sports, she is a half marathon runner and a triathlete. Always enthusiastic about transmitting her passion for health and business development, this project is 'her new baby'.

Mr. Babin brings expertise and an excellent record of success in national and International business development. His personal list of contacts - people that he knows and can call and talk to directly - boasts of ministers of finance, ministers of health, and owners of laboratories and pharmacies. Mr. Babin is also an expert in electronics, and has experience in employee and staff management.

Initially, the MSN-2 medical device will be distributed overseas in drugstores and via the internet. Distribution in North and South American countries will commence when all necessary regulatory issues have been settled. 

In other sector related news for medicinal cannabis and legal medical marijuana market performances and developments:

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) closed up on Monday at $20.77 trading over 450,000 shares by the market close. Zynerba Pharmaceuticals, a clinical-stage specialty pharmaceutical company, dedicated to the development of innovative transdermal synthetic cannabinoid treatments, on Monday announced that the company will report its fourth quarter and full-year 2016 financial results and recent operating progress on Monday, March 27, 2017. Management will host a conference call and webcast at 8:30 am ET. To participate in the call, please dial (844) 815-4960 (domestic) or (210) 229-8835 (international) and reference conference ID 84591304. A live webcast will be available on the Investor Relations page of the Company's website, http://www.zynerba.com, and a replay will be available for 30 days.

CV Sciences, Inc. (OTCQB: CVSI) closed up slightly on Monday at $0.37 by the market close. CV Sciences, Inc., a preeminent supplier and manufacturer of hemp-derived CBD oil bulk and consumer products, on Monday announced the launch of the first online education platform designed to enhance its brand education and advocacy, through Experticity. Currently over 750 consumer brands, including The North Face, Dyson, and Quiksilver, are working with Experticity to educate and tap into real-life experts (industry professionals, category opinion leaders, online influencers and passionate retail sales associates), to create a new breed of buying experience -- one that is informed, genuine and mutually beneficial for retailers and consumers. CV Sciences' education platform will cover a variety of topics pertaining to hemp, phytocannabinoids, and its industry-dominating consumer products brand, PlusCBD Oil™.

Medical Marijuana, Inc. (OTC: MJNA) closed up over 5% on Monday trading over 9.9 Million shares by the market close. Medical Marijuana, Inc., the first-ever publicly traded cannabis company in the United States , announced last week that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM) has enrolled 40 patients and commenced its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS), with the company's CanChew Plus® CBD gum. The study is being conducted by Renger Witkamp, Professor and Chair in Nutrition and Pharmacology, at Wageningen University in the Netherlands.

In other Biotech leading developments and major performance for the day in Monday's trade:

Cerulean Pharma Inc. (NASDAQ: CERU) closed up over 63% on Monday at $2.49 trading over 31.6 Million shares by the market close.  Cerulean is committed to improving treatment for people living with cancer. Cerulean Pharma applies its Dynamic Tumor Targeting™ platform, to create a portfolio of nanoparticle-drug conjugates (NDCs) designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Cerulean's first platform-generated NDC clinical candidate, CRLX101, is in clinical trials in combination with other cancer treatments, all of which aim to unlock the power of combination therapy. Cerulean's second platform-generated NDC clinical candidate, CRLX301, is in a Phase 1/2a clinical trial.

DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated three thousand nine hundred dollars for news coverage of the current press release issued by Earth Science Tech, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.

Contact Information: Media Contact E-mail: info@marketnewsupdates.com - Phone: +1(561)325-8757

SOURCE MarketNewsUpdates.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook